These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27629941)

  • 1. Dialyzability of Faropenem in Infected Patients on Chronic Hemodialysis.
    Hasegawa G; Tsuruoka S; Ushijima K; Maeda A; Hayasaka T; Saito T; Harada K; Fujimura A
    Ther Apher Dial; 2017 Feb; 21(1):52-56. PubMed ID: 27629941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dialyzability and pharmacokinetics of sitafloxacin following multiple oral dosing in infected hemodialysis patients.
    Tsuruoka S; Yokota N; Hayasaka T; Saito T; Yamagata K
    Ther Apher Dial; 2013 Jun; 17(3):319-24. PubMed ID: 23735148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains].
    Nasu T; Okamoto K; Nakanishi T; Nishino T
    Jpn J Antibiot; 1999 Aug; 52(8):541-53. PubMed ID: 10587879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FHD: an index to evaluate drug elimination by hemodialysis.
    Launay-Vacher V; Izzedine H; Baumelou A; Deray G
    Am J Nephrol; 2005; 25(4):342-51. PubMed ID: 15980618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].
    Muratani T; Iihara K; Nishimura T; Inatomi H; Fujimoto N; Kobayashi T; Yamada Y; Takahashi K; Matsumoto T
    Kansenshogaku Zasshi; 2002 Nov; 76(11):928-38. PubMed ID: 12508476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates].
    Matsuzaki K; Nishiyama T; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 May; 52(5):431-8. PubMed ID: 10480050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases].
    Yokota T; Azagami S; Abe T; Ozaki A; Ojima T; Koizumi Y; Jozaki K; Cho H; Nakao A; Nonoyama M; Bamba M; Hojo H; Sunakawa K
    Jpn J Antibiot; 2008 Dec; 61(6):366-78. PubMed ID: 19288854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of faropenem against infections in pediatric fields].
    Sunakawa K; Satoh Y; Iwata S; Terashima I; Meguro H; Kusumoto Y; Kato T; Akita H; Goshima T; Yokota T; Toyonaga Y; Ishihara T; Kanemura H; Iwai N; Nakamura H; Nakashima M
    Jpn J Antibiot; 1997 Sep; 50(9):739-55. PubMed ID: 9394235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
    El-Assal MI; Helmy SA
    Biopharm Drug Dispos; 2014 Oct; 35(7):405-16. PubMed ID: 25044219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of faropenem for patients with acute cystitis caused by extended spectrum β-lactamase producing Escherichia coli.
    Fujino K; Hiyama Y; Uehara T; Ichihara K; Hashimoto J; Fujii S; Shinagawa M; Takahashi S; Masumori N
    J Infect Chemother; 2017 May; 23(5):336-338. PubMed ID: 27916471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of drug dialyzability in a rat model of hemodialysis.
    Fukunaga M; Kadowaki D; Mori M; Hagiwara S; Narita Y; Saruwatari J; Tanaka R; Watanabe H; Yamasaki K; Taguchi K; Ito H; Maruyama T; Otagiri M; Hirata S
    PLoS One; 2020; 15(6):e0233925. PubMed ID: 32530952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
    Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
    Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis.
    Ijiri Y; Inoue T; Fukuda F; Suzuki K; Kobayashi T; Shibahara N; Takenaka H; Tanaka K
    Epilepsia; 2004 Aug; 45(8):924-7. PubMed ID: 15270757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.
    Hadley JA; Tillotson GS; Tosiello R; Echols RM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):923-37. PubMed ID: 17181408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR.
    García Moreira V; de la Cera Martínez T; Gago González E; Prieto García B; Alvarez Menéndez FV
    Clin Chem Lab Med; 2006; 44(12):1410-5. PubMed ID: 17163815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients.
    Oldani S; Finazzi S; Bottazzi B; Garlanda C; Baldassarre E; Valaperta S; Cuccovillo I; Albini M; Child M; Montanelli A; Graziani G; Badalamenti S
    J Nephrol; 2012; 25(1):120-6. PubMed ID: 21725917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.